| abstract |
The present invention is directed to a combination therapy comprising metformin eicosapentaenoate or metformin docosahexaenoate, or a mixture thereof, and an antihyperglycemic agent or an antihyperlipidemic agent, or a pharmaceutically-acceptable salt or prodrug thereof, or a pharmaceutically-acceptable salt of said prodrug. The invention further relates to methods of treating a metabolic disorder selected from the group consisting of type 2 diabetes (T2D), pre-diabetes, obesity, metabolic syndrome, hypertrilipidemia and T2D complications such as neuropathy, nephropathy, retinopathy, cataracts and cardiovascular complications, including cardiac arrhythmia, myocardial infarction, stroke, and cardiomyopathy in diabetic patients. |